{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=stem+cell+infusion&page=36", "query": { "intervention": "stem cell infusion", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 1174, "total_pages": 118, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=stem+cell+infusion&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=stem+cell+infusion&page=35&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T18:00:40.141Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00499343", "title": "G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "Isophosphamide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 84, "start_date": "2004-01", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-11-15T18:00:40.141Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499343" }, { "nct_id": "NCT00186914", "title": "Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Osteodysplasia" ], "interventions": [ { "name": "Marrow stromal cell infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 8, "start_date": "1999-07", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2015-03-04", "last_synced_at": "2026-11-15T18:00:40.141Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00186914" }, { "nct_id": "NCT02259348", "title": "Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia (ALL)", "Acute Myeloid Leukemia (AML)", "Myeloid Sarcoma", "Chronic Myelogenous Leukemia (CML)", "Juvenile Myelomonocytic Leukemia (JMML)", "Myelodysplastic Syndrome (MDS)", "Non-Hodgkin Lymphoma (NHL)" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "Interleukin-2", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Natural killer cell therapy", "type": "BIOLOGICAL" }, { "name": "T-cell depleted HPC transplant", "type": "BIOLOGICAL" }, { "name": "CD45RA-depleted HPC transplant", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 12, "start_date": "2014-10", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-11-15T18:00:40.141Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02259348" }, { "nct_id": "NCT01297543", "title": "Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia", "Myelodysplasia" ], "interventions": [ { "name": "human myeloid progenitor cells", "type": "BIOLOGICAL" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Cellerant Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2011-03", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2016-07-01", "last_synced_at": "2026-11-15T18:00:40.141Z", "location_count": 10, "location_summary": "La Jolla, California • San Francisco, California • Stanford, California + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Beech Grove", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01297543" }, { "nct_id": "NCT01453088", "title": "Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 63, "start_date": "2010-06-24", "completion_date": "2022-05-01", "has_results": true, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-11-15T18:00:40.141Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01453088" }, { "nct_id": "NCT07616154", "title": "Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Cyclophosphamide 50mg", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "TBI", "type": "RADIATION" }, { "name": "Hematopoietic Progenitor Cell Infusion", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 45, "start_date": "2026-09-10", "completion_date": "2035-09", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T18:00:40.141Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07616154" }, { "nct_id": "NCT03514537", "title": "Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Frailty-Aging Processes", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Frail Elderly Syndrome", "Aging", "Degenerative Disease" ], "interventions": [ { "name": "Microcannula harvest adipose stromal tissues", "type": "PROCEDURE" }, { "name": "Centricyte 1000", "type": "DEVICE" }, { "name": "Sterile Normal Saline IV Deployment of cSVF", "type": "PROCEDURE" }, { "name": "Liberase", "type": "DRUG" }, { "name": "Saline Solution", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DEVICE", "DRUG" ], "sponsor": "Healeon Medical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "40 Years to 90 Years" }, "enrollment_count": 200, "start_date": "2018-03-15", "completion_date": "2028-01-15", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-11-15T18:00:40.141Z", "location_count": 1, "location_summary": "Colchester, Vermont", "locations": [ { "city": "Colchester", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT03514537" }, { "nct_id": "NCT01656603", "title": "Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infusion Reactions" ], "interventions": [ { "name": "unlicensed CBU", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "New York Blood Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 9999, "start_date": "2012-02", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-11-15T18:00:40.141Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01656603" }, { "nct_id": "NCT01821781", "title": "Immune Disorder HSCT Protocol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immune Deficiency Disorders", "Severe Combined Immunodeficiency", "Chronic Granulomatous Disease", "X-linked Agammaglobulinemia", "Wiskott-Aldrich Syndrome", "Hyper-IgM", "DiGeorge Syndrome", "Chediak-Higashi Syndrome", "Common Variable Immune Deficiency", "Immune Dysregulatory Disorders", "Hemophagocytic Lymphohistiocytosis", "IPEX", "Autoimmune Lymphoproliferative Syndrome", "X-linked Lymphoproliferative Syndrome" ], "interventions": [ { "name": "Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 28, "start_date": "2013-04-29", "completion_date": "2026-04-23", "has_results": true, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-15T18:00:40.141Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01821781" }, { "nct_id": "NCT05018819", "title": "Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cerebral Palsy" ], "interventions": [ { "name": "cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "The Foundation for Orthopaedics and Regenerative Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "2022-02-01", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-15T18:00:40.141Z", "location_count": 1, "location_summary": "Naples, Florida", "locations": [ { "city": "Naples", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05018819" } ] }